Glucocorticoid Repression of Inflammatory Gene Expression Shows Differential Responsiveness by Transactivation- and Transrepression-Dependent Mechanisms

Binding of glucocorticoid to the glucocorticoid receptor (GR/NR3C1) may repress inflammatory gene transcription via direct, protein synthesis-independent processes (transrepression), or by activating transcription (transactivation) of multiple anti-inflammatory/repressive factors. Using human pulmonary A549 cells, we showed that 34 out of 39 IL-1β-inducible mRNAs were repressed to varying degrees by the synthetic glucocorticoid, dexamethasone. Whilst these repressive effects were GR-dependent, they did not correlate with either the magnitude of IL-1β-inducibility or the NF-κB-dependence of the inflammatory genes. This suggests that induction by IL-1β and repression by dexamethasone are independent events. Roles for transactivation were investigated using the protein synthesis inhibitor, cycloheximide. However, cycloheximide reduced the IL-1β-dependent expression of 13 mRNAs, which, along with the 5 not showing repression by dexamethasone, were not analysed further. Of the remaining 21 inflammatory mRNAs, cycloheximide significantly attenuated the dexamethasone-dependent repression of 11 mRNAs that also showed a marked time-dependence to their repression. Such effects are consistent with repression occurring via the de novo synthesis of a new product, or products, which subsequently cause repression (i.e., repression via a transactivation mechanism). Conversely, 10 mRNAs showed completely cycloheximide-independent, and time-independent, repression by dexamethasone. This is consistent with direct GR transrepression. Importantly, the inflammatory mRNAs showing attenuated repression by dexamethasone in the presence of cycloheximide also showed a significantly greater extent of repression and a higher potency to dexamethasone compared to those mRNAs showing cycloheximide-independent repression. This suggests that the repression of inflammatory mRNAs by GR transactivation-dependent mechanisms accounts for the greatest levels of repression and the most potent repression by dexamethasone. In conclusion, our data indicate roles for both transrepression and transactivation in the glucocorticoid-dependent repression of inflammatory gene expression. However, transactivation appears to account for the more potent and efficacious mechanism of repression by glucocorticoids on these IL-1β-induced genes.

[1]  M. Belvisi,et al.  Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. , 2012, Pharmacology & therapeutics.

[2]  P. O'Byrne,et al.  Corticosteroid‐induced gene expression in allergen‐challenged asthmatic subjects taking inhaled budesonide , 2012, British journal of pharmacology.

[3]  M. Ushio-Fukai,et al.  Superoxide dismutases: role in redox signaling, vascular function, and diseases. , 2011, Antioxidants & redox signaling.

[4]  G. van Loo,et al.  Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. , 2011, Biochemical Society transactions.

[5]  P. Barnes.  Glucocorticosteroids: current and future directions , 2011, British journal of pharmacology.

[6]  P. Chambon,et al.  Widespread Negative Response Elements Mediate Direct Repression by Agonist- Liganded Glucocorticoid Receptor , 2011, Cell.

[7]  E. Moilanen,et al.  Mitogen-Activated Protein Kinase Phosphatase-1 Negatively Regulates the Expression of Interleukin-6, Interleukin-8, and Cyclooxygenase-2 in A549 Human Lung Epithelial Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[8]  W. Gong,et al.  Glucocorticoids inhibit IL-1beta-induced GM-CSF expression at multiple levels: roles for the ERK pathway and repression by MKP-1. , 2010, The Biochemical journal.

[9]  J. Steinke,et al.  Immunologic messenger molecules: cytokines, interferons, and chemokines. , 2010, The Journal of allergy and clinical immunology.

[10]  R. Leigh,et al.  Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. , 2010, Pharmacology & therapeutics.

[11]  Richard M Myers,et al.  Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. , 2009, Genome research.

[12]  C. Riccardi,et al.  Glucocorticoid‐induced leucine zipper (GILZ): a new important mediator of glucocorticoid action , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  I. Wicks,et al.  G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[14]  W. Gong,et al.  Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. , 2009, The Journal of biological chemistry.

[15]  W. Gong,et al.  Regulation of Tristetraprolin Expression by Interleukin-1β and Dexamethasone in Human Pulmonary Epithelial Cells: Roles for Nuclear Factor-κB and p38 Mitogen-Activated Protein Kinase , 2009, Journal of Pharmacology and Experimental Therapeutics.

[16]  M. Craighead,et al.  Differential Effects of the New Glucocorticoid Receptor Antagonist ORG 34517 and RU486 (Mifepristone) on Glucocorticoid Receptor Nuclear Translocation in the AtT20 Cell Line , 2008, Annals of the New York Academy of Sciences.

[17]  A. Clark,et al.  Role of Dual Specificity Phosphatases in Biological Responses to Glucocorticoids* , 2008, Journal of Biological Chemistry.

[18]  P. Herrlich,et al.  Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. , 2008, Molecular endocrinology.

[19]  A. Ammit,et al.  Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. , 2008, American journal of respiratory cell and molecular biology.

[20]  S. B. Cooper,et al.  Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes , 2008, Proceedings of the National Academy of Sciences.

[21]  J. Chivers,et al.  Long-Acting β2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells , 2008, Molecular Pharmacology.

[22]  N. Holden,et al.  Potentiation of NF‐κB‐dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells , 2007 .

[23]  N. Holden,et al.  Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor? , 2007, Molecular Pharmacology.

[24]  A. Clark.  Anti-inflammatory functions of glucocorticoid-induced genes , 2007, Molecular and Cellular Endocrinology.

[25]  I. Adcock,et al.  Corticosteroid Inhibition of Growth-Related Oncogene Protein-α via Mitogen-Activated Kinase Phosphatase-1 in Airway Smooth Muscle Cells1 , 2007, The Journal of Immunology.

[26]  C. Riccardi,et al.  GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. , 2007, The Journal of clinical investigation.

[27]  W. Gong,et al.  Analysis of the Dissociated Steroid RU24858 Does Not Exclude a Role for Inducible Genes in the Anti-Inflammatory Actions of Glucocorticoids , 2006, Molecular Pharmacology.

[28]  D. Figarella-Branger,et al.  Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. , 2006, Genes & development.

[29]  K. Honda,et al.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors , 2006, Nature Reviews Immunology.

[30]  K. Chung,et al.  Validation of the Anti-Inflammatory Properties of Small-Molecule IκB Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle , 2006, Molecular Pharmacology.

[31]  E. Gelfand,et al.  Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Barnes.  Corticosteroids: the drugs to beat. , 2006, European journal of pharmacology.

[33]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[34]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[35]  K. Yamamoto,et al.  The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. , 2005, Genes & development.

[36]  P. Barnes,et al.  Validation of IKKβ as therapeutic target in airway inflammatory disease by adenoviral‐mediated delivery of dominant‐negative IKKβ to pulmonary epithelial cells , 2005 .

[37]  K. Chung,et al.  Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-γ and TNF-α and regulation by TGF-β and corticosteroids , 2004 .

[38]  K. Yamamoto,et al.  Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Haegeman,et al.  The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. , 2003, Endocrine reviews.

[40]  T. Hofmann,et al.  The Promoter Context Determines Mutual Repression or Synergism between NF-κB and the Glucocorticoid Receptor , 2002, Biological chemistry.

[41]  J. Saklatvala,et al.  Dexamethasone Causes Sustained Expression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated Inhibition of MAPK p38 , 2002, Molecular and Cellular Biology.

[42]  T. Burn,et al.  Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. , 2002, Endocrinology.

[43]  K. Chung,et al.  Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone. , 2002, European journal of pharmacology.

[44]  O. Kassel,et al.  Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP‐1 , 2001, The EMBO journal.

[45]  J. Ashwell,et al.  Inhibition of AP-1 by the Glucocorticoid-inducible Protein GILZ* , 2001, The Journal of Biological Chemistry.

[46]  C. Riccardi,et al.  Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. , 2001, Blood.

[47]  K. Yamamoto,et al.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. , 2000, Genes & development.

[48]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[49]  R. Newton.  Molecular mechanisms of glucocorticoid action: what is important? , 2000, Thorax.

[50]  I. Adcock,et al.  Effect of dexamethasone on interleukin‐1β‐(IL‐1β)‐induced nuclear factor‐κB (NF‐κB) and κB‐dependent transcription in epithelial cells , 1998 .

[51]  S. Farrow,et al.  Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. , 1997, The Biochemical journal.

[52]  P. Herrlich,et al.  IκBα‐independent downregulation of NF‐κB activity by glucocorticoid receptor , 1997, The EMBO journal.

[53]  K. Lei,et al.  Dexamethasone potently enhances phorbol ester-induced IL-1beta gene expression and nuclear factor NF-kappaB activation. , 1997, Journal of immunology.

[54]  F. Bach,et al.  Glucocorticoid-mediated Repression of NFκB Activity in Endothelial Cells Does Not Involve Induction of IκBα Synthesis* , 1996, The Journal of Biological Chemistry.

[55]  A. Baldwin,et al.  Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.

[56]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[57]  I. Adcock,et al.  Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. , 1994, Immunology.

[58]  A. Ray,et al.  Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Drouin,et al.  Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription , 1989, Molecular and cellular biology.

[60]  K. Yamamoto,et al.  Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. , 1988, Genes & development.

[61]  J. Chivers,et al.  Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. , 2008, Molecular pharmacology.

[62]  B. Zuraw,et al.  The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. , 2007, The Journal of allergy and clinical immunology.

[63]  W. Gong,et al.  Potentiation of NF-kappaB-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells. , 2007, British journal of pharmacology.

[64]  P. Barnes,et al.  Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. , 2005, British journal of pharmacology.

[65]  C. Stellato.  Post-transcriptional and nongenomic effects of glucocorticoids. , 2004, Proceedings of the American Thoracic Society.

[66]  R. Schleimer.  Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. , 2004, Proceedings of the American Thoracic Society.

[67]  K. Chung,et al.  Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[68]  I. Adcock,et al.  Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. , 1998, European journal of biochemistry.

[69]  F. Bach,et al.  Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. , 1996, The Journal of biological chemistry.

[70]  M. Karin,et al.  Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. , 1995, Science.

[71]  A. Baldwin,et al.  Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. , 1995, Science.

[72]  W. Bartholomew,et al.  Complement components and receptors: deficiencies and disease associations. , 1990, Immunology series.

[73]  Shanahan Tc,et al.  Complement components and receptors: deficiencies and disease associations. , 1990, Immunology series.